Jared Galloway
Internal Medicine · Cincinnati, OHNPI 1114487758
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,636, 3.9 times the $417 reported in 2022.
Across 230 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$524
- AstraZeneca$507
- AbbVie$415
- Lilly USA, LLC$366
- Exact Sciences$365
- Pfizer$315
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,934100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $524 |
| AstraZeneca | 13 | $507 |
| AbbVie | 30 | $415 |
| Lilly USA, LLC | 25 | $366 |
| Exact Sciences | 23 | $365 |
| Pfizer | 22 | $315 |
| GSK | 19 | $299 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $190 |
| Bayer | 7 | $128 |
| Teva Pharmaceuticals USA, Inc. | 6 | $112 |
| Boehringer Ingelheim | 6 | $99 |
| Philips North America LLC | 5 | $97 |
| Dexcom, Inc. | 4 | $87 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Lundbeck LLC | 3 | $57 |
| Amgen | 2 | $49 |
| Gilead | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Abiomed | 1 | $25 |
| Astellas Pharma US Inc | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Novartis | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$340
- AIRSUPRA$210
- BREZTRI$210
- FLUMIST QUADRIVALENT$130
How this compares
$3,934 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $143,784 |
| JardianceEmpagliflozin | 94 | $92,107 |
| FarxigaDapagliflozin Propanediol | 102 | $85,583 |
| OzempicSemaglutide | 63 | $58,911 |
| TrulicityDulaglutide | 50 | $54,297 |
| RybelsusSemaglutide | 46 | $50,035 |
| Teriparatide | 12 | $42,729 |
| XareltoRivaroxaban | 33 | $39,977 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $33,507 |
| Nurtec OdtRimegepant Sulfate | 18 | $32,945 |
| LinzessLinaclotide | 26 | $24,033 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $21,380 |
| JanuviaSitagliptin Phosphate | 19 | $20,007 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,195 |
| VraylarCariprazine Hcl | 13 | $17,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $315 | $176,729158 claims |
| Novo NordiskOzempic, Rybelsus | $524 | $108,946109 claims |
| Boehringer IngelheimJardiance, Tradjenta | $99 | $107,247109 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $507 | $102,779128 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $366 | $65,14062 claims |
| Johnson & JohnsonXarelto, Invokana | $12 | $56,10849 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $299 | $43,21768 claims |
| AbbVieLinzess, Vraylar | $415 | $41,12139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cincinnati
- Lisa LarkinCincinnati$276K
- Vincent MartinCincinnati$261K
- Kay JohnsonCincinnati$184K
- Jason HatfieldCincinnati$72K
- Rajbir MinhasCincinnati$62K
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.